4.3 Article

Interleukin-6 Promotes Epithelial-Mesenchymal Transition and Cell Invasion through Integrin β6 Upregulation in Colorectal Cancer

Journal

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
Volume 2020, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2020/8032187

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [81702362, 81803026]
  2. China Postdoctoral Science Foundation [2019T120922, 2018M631176]
  3. Key Research and Development Program of Shaanxi [2019KW-067]
  4. Shaanxi Province Postdoctoral Science Foundation [2018BSHYDZZ49]
  5. Natural Science Foundation of Shandong Province of China [ZR2017BH072, ZR2017BH095]

Ask authors/readers for more resources

The metastatic potential of colorectal cancer (CRC) is intensively promoted by the tumor microenvironment (TME) in a paracrine manner. As a pleiotropic inflammatory cytokine, Interleukin-6 (IL-6) is produced and involved in CRC, the same scenario where integrin alpha v beta 6 also becomes upregulated. However, the relationship between IL-6 and integrin alpha v beta 6 as well as their involvement in the crosstalk between CRC and TME remains largely unclear. In the present study, we demonstrated a positive correlation between the expression of IL-6 and integrin beta 6 in CRC samples. The mutually promotive interaction between CRC and TME was further determined by an indirect coculture system. CRC cells could augment the secretion of IL-6 from fibroblasts, which in return induced invasion and integrin beta 6 expression of CRC cells. Through the classic IL-6 receptor/STAT-3 signaling pathway, IL-6 mediated the upregulation of integrin beta 6, which was involved in the invasion and epithelial-mesenchymal transition of CRC cells induced by IL-6. Taken together, our results reveal a paracrine crosstalk between IL-6 signals originating from the TME and increased the integrin beta 6 level of CRC. IL-6 induces CRC invasion via upregulation of integrin beta 6 through the IL-6 receptor/STAT-3 signaling pathway. Combined inhibition of IL-6 along with integrin beta 6-targeted strategy may indicate new directions for antitumor strategies for CRC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available